Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 13,615 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Locally Advanced or Metastatic Solid Tumor
Interventions: Rebastinib, Carboplatin; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: San Francisco, California • Santa Monica, California • Chicago, Illinois + 6 more

Conditions: Melanoma
Interventions: Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 7 more

Conditions: Hidradenitis Suppurativa
Interventions: Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more

Conditions: Venous Leg Ulcers
Interventions: PRP Concepts Fibrin Bio-Matrix, Usual and Customary Practice; Device · Other
Lead sponsor: PRP Concepts, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma (Skin)
Interventions: Interferon alfa, Radiation therapy; Biological · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 2
States / cities: Miami, Florida • Tampa, Florida

Conditions: Breast Cancer
Interventions: sunitinib, capecitabine, WBRT; Drug · Radiation
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Questionnaires, Yoga Classes; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lobular Breast Carcinoma
Interventions: 18Fluoroestradiol (18F-FES), MRI, Gadolinium-based contrast agent (GBCA); Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Systemic Sclerosis
Interventions: MK-2225, Placebo; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Springfield, Missouri

Conditions: Melanoma, Young Adult
Interventions: MC1R Genetic Testing, Skin Cancer Education, UV Photo; Diagnostic Test · Other · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hereditary Angioedema, HAE
Interventions: BCX7353 capsules, Placebo oral capsule; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more

Conditions: Epidermolysis Bullosa
Interventions: busulfan, cyclophosphamide, fludarabine phosphate, hematopoietic bone marrow transplantation; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 25 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: Healing Touch, Standard care, guided relaxation; Procedure · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Standard of care treatment, eculizumab; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Psoriasis
Interventions: Placebo, Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more

Conditions: Diabetic Foot, Ulcer Foot, Wound Heal
Interventions: Wound debridement, Wound closure matrix application; Procedure · Device
Lead sponsor: Polymedics Innovations Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Circleville, Ohio

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Interventions: Non-interventional Study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 488
States / cities: Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 378 more

Conditions: Pemphigus Vulgaris
Interventions: Dapsone; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 8
States / cities: Chicago, Illinois • Detroit, Michigan • Camden, New Jersey + 4 more

Conditions: Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Pembrolizumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Radiation Therapy
Interventions: oral colchicine(0.6 mg) once a day; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Livingston, New Jersey • New Brunswick, New Jersey

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions: mistletoe extract, gemcitabine hydrochloride; Dietary Supplement · Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tightening of Skin Laxity
Interventions: Apsara Thermal Wand System; Device
Lead sponsor: Apsara Medical Corporation; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Letrozole, Everolimus, TRC105; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Venous Leg Ulcers

Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa

Brain Mets - Capecitabine Plus Sunitinib and WBRT

Yoga for Aromatase Inhibitor-associated Joint Pain

FES PET/MRI for Occult Disease in Lobular Breast Cancer

A Study of MK-2225 in Healthy Participants (MK-2225-003)

Risk Information and Skin-cancer Education for Undergraduate Prevention

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

Healing Touch During Chemotherapy Infusions for Women With Breast Cancer

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

SDRM® vs. Collagen for Diabetic Foot Ulcers

Following the Use of Gel Prosethetics in Breast Reconstruction

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Study to Evaluate the Safety of Colchicine

Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors

Application of the Apsara Thermal Wand System

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer